The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. Keeping that in mind, here are three value stocks with little support and some other investments you should consider instead.
Health Catalyst (HCAT)
Forward P/S Ratio: 0.7x
Built on its "Health Catalyst Flywheel" methodology that emphasizes measurable outcomes, Health Catalyst (NASDAQ: HCAT) provides data and analytics technology and services that help healthcare organizations manage their data and drive measurable clinical, financial, and operational improvements.
Why Are We Out on HCAT?
- Flat billings over the last year suggest it may need to improve its products, pricing, or go-to-market strategy to reinvigorate demand
- Bad unit economics and steep infrastructure costs are reflected in its gross margin of 50.4%, one of the worst among software companies
- Customer acquisition costs take a while to recoup, making it difficult to justify sales and marketing investments that could increase revenue
Health Catalyst is trading at $2.30 per share, or 0.7x forward price-to-sales. If you’re considering HCAT for your portfolio, see our FREE research report to learn more.
Churchill Downs (CHDN)
Forward P/E Ratio: 12x
Famous for hosting the Kentucky Derby, Churchill Downs (NASDAQ: CHDN) operates a horse racing, online wagering, and gaming entertainment business in the United States.
Why Should You Dump CHDN?
- Muted 8.7% annual revenue growth over the last two years shows its demand lagged behind its consumer discretionary peers
- Poor free cash flow margin of 14.9% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
- Improving returns on capital suggest management is identifying more profitable investments
At $84.55 per share, Churchill Downs trades at 12x forward P/E. Dive into our free research report to see why there are better opportunities than CHDN.
Jazz Pharmaceuticals (JAZZ)
Forward P/E Ratio: 9.7x
Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.
Why Does JAZZ Give Us Pause?
- Sales trends were unexciting over the last two years as its 7.5% annual growth was below the typical healthcare company
- Costs have risen faster than its revenue over the last five years, causing its adjusted operating margin to decline by 21.5 percentage points
- Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 4.2% annually
Jazz Pharmaceuticals’s stock price of $239.43 implies a valuation ratio of 9.7x forward P/E. Check out our free in-depth research report to learn more about why JAZZ doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
